Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response

Gut

Volumn 54, Issue 6, 2005, Pages 858-866

  Kamal, S M ^a,b   El Tawil, A A ^a   Nakano, T ^c,d   He, Q ^b   Rasenack, J ^e   Hakam, S A ^a   Saleh, W A ^a   Ismail, A ^a   Aziz, A A ^a   Madwar, M Ali ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Ichinomiya Nishi Hospital   (Japan)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABDOMINAL PAIN; AFRICA; ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE EAST; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RIGOR; SORE THROAT; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; VIRUS LOAD; VOMITING; XEROSTOMIA;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MULTIVARIATE ANALYSIS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 21144449073     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.057182     Document Type: Article

References (30)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000;32:111-15.
3. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
4. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
5. Bhattacherjee V, Prescott LE, Pike I, et al. Use of NS-4 peptides to identify type specific antibody to hepatitis C virus genotypes 1, 2, 3,4,5 and 6. J Gen Virol 1995;76:1737-48.
6. Habib M, Mohamed MK, Abdel-Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001;33:248-53.
7. Kamal S, Madwar M, Bianchi L, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000;20:281-90.
8. Angelico M, Renganathan E, Gandin C, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997;26:236-43.
9. Morice Y, Roulot D, Grando V, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 2001;82(Pt 5):1001-12.
10. Lyra AC, Ramrakhiani S, Bacon BR, et al. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004;38:68-71.
11. Chamberlain R, Adams N, Saeed A, et al. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 2004;78:1341-7.
12. Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000;182:698-707.
13. El-Zayadi A, Selim O, Haddad S, et al. Combination treatment of interferon α-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999;31:472-5.
14. Kamal SM, Madwar MA, Peters T, et al. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000;32:172-4.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
17. Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004;41:474-81.
18. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med 2004;140:346-55.
19. Halfon P, Neumann AU, Bourliere M, et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat 2003;10:351-3.
20. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-8.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
22. El-Zayadi A, Simmonds P, Dabbous H, et al. Response to interferon-α of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996;3:261-4.
23. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7.
24. Shobokshi OA, Serebour FE, Skakni L, et al. Pegylated interferon alfa-2a (40kDa) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Med J 2003;24(suppl 2):S92.
25. Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or in combination with ribavirin enhances HCV specific CD4+ T helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83.
26. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1546-9.
27. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504-8.
28. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.
29. Poynard T. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C. Gut 2003;52:1532.
30. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.